Social Acceptance of Cosmetic Procedures Driving Botox Use in Europe

More doctors are performing botulinum toxin procedures due to popular demand for beauty treatments.

Waltham, MA (PRWEB) August 8, 2006 -- Millennium Research Group, the global authority on medical technology market intelligence, finds that the European facial aesthetics market, comprising botulinum toxin (BTX), hyaluronic acid (HA), collagen, and particle and polymer-based cosmetic injectables, was valued at over $150 million in 2005. According to the new report entitled, European Markets for Facial Aesthetics 2006, this market will continue to grow over the next 5 years due to favorable attitudes towards aesthetic enhancement and augmentation among most of the European population.

In 2005, the BTX market was one of the largest segments of the facial aesthetic market in Europe which includes France, Germany, Italy, and the United Kingdom. Growth has been driven in large part by increased disposable income and by the aging baby boomer demographic who are seeking to maintain a youthful appearance. Moreover, access to these procedures has increased both physically and financially in Europe. Not only are more doctors performing these procedures due to demand for popular beauty treatments, but prices are also decreasing in many countries, making the procedures more economically accessible for consumers. Because BTX only lasts between 3 to 6 months, patients must repeat the procedure to maintain its cosmetic effects, resulting in a continued revenue source for manufacturers in this market.

Millennium Research Group’s European Markets for Facial Aesthetics 2006 report is part of the Global Markets for Facial Aesthetics series, which also includes analysis on the US, Latin America, and Asia Pacific markets. The series covers various key industry competitors, such as Q-Med (QMED), Allergan-Inamed (AGN), Corneal, Bioform, Ipsen (IPN), Procytech, Merz Pharmaceutical, Contura, Sanofi-Aventis (SNY), and Fidia.

About Botulinum Toxin
Botulinum toxin, scientifically known as Clostridium botulinum, is a lethal neurotoxin discovered nearly 100 years ago in poorly canned food. The BTX neurotoxin works to impede muscle contraction by binding and blocking the action of muscle neurons that fire neurotransmitters, resulting in relaxation of the targeted muscles.

About Millennium Research Group
Millennium Research Group (www.MRG.net) is a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn
Millennium Research Group
416-364-7776 x101

# # #